Posts Tagged ‘Zepbound’

Novo Nordisk Obesity Sales Drop, Stock Rises, Go Figure

May 7, 2025 — The word of the day in obesity is volatility. Minutes ago in Denmark, Novo Nordisk announced their first quarter business results and revealed a 13% drop in obesity drug sales, a reduction in their sales forecast, and yet the response in European stock markets was that the stock rose in value. In fact, it rose […]

Lilly Withdraws Tirzepatide Application to FDA for Heart Failure

May 3, 2025 — Rather quietly this week, Eli Lilly and Company announced that it had withdrawn an application to FDA for an indication to use tirzepatide (Zepbound) in treating heart failure – specifically for HFpEF. This news came up in a briefing for investors, with Lilly’s Chief Scientific Officer, Dan Skovronsky, saying: “Following discussions with the FDA, we’ve […]

As Legitimate GLP-1 Compounding Ends, Rabbit Holes Open Up

May 2, 2025 — The last legitimate path for GLP-1 compounding closes on May 22 and consumer protection advocates are worried about rabbit holes opening up to exploit the desperation of some patients. Yesterday, the National Consumer League (NCL) released survey results to suggest a great deal of confusion and misinformation about off-brand versions of GLP-1 medicines. Perhaps more […]

Price and Value Out of Whack for Wegovy and Zepbound

March 15, 2025 — A new analysis in JAMA Health Forum yesterday shines a harsh light on pricing for new obesity medicines. In a rigorous econometric analysis, researchers found that new and highly effective medicines for obesity – Wegovy (semaglutide) and Zepbound (tirzepatide) – are both overpriced. They also found that the price and value of Wegovy was out […]

A Huge Price Cut on Wegovy for Cash-Paying Patients

March 6, 2025 — Prices are moving quickly for people seeking obesity treatment with semaglutide and tirzepatide. Last week, Lilly offered another price cut for Zepbound. At the time, we noted inaction from Novo Nordisk on this front. But it barely took a week for this formerly unchallenged market leader to step up and respond with a huge price […]

Another Selective Price Cut for Zepbound from Lilly

February 26, 2025 — Just days after an FDA ruling that will force most compounders out of the market for obesity medicines, Eli Lilly announced yet another carefully calibrated price cut for its Zepbound brand of tirzepatide. These are direct-to-consumer prices for the product packaged in vials. Specifically, Lilly offered up two new, higher dose vials at a reduced […]

Moving from Hype to Realities in the Obesity Market

February 7, 2025 — Novo Nordisk and Lilly reported on their business results this week for the final quarter of 2024. These reports brought clarity on a number of points, but to us, one thing stands out. We are moving from euphoria and hype about limitless possibilities in obesity to the realities of market competition and incremental progress. Sales […]

New Year, New and Higher List Prices for GLP-1 Medicines

January 16, 2025 — This will be an interesting year for drug pricing, especially for obesity medicines – if you can even figure out what is really going on with them. It appears that list prices for Ozempic (semaglutide), Mounjaro (tirzepatide), and Zepbound (also tirzepatide) have all gone up this year. The Wegovy (semaglutide) list price did not change. […]

Sleep Apnea Takes Zepbound from No to Maybe in Medicare

January 12, 2025 — Last week we got another glimpse of incremental progress in coverage for obesity medicines in health insurance plans. CMS announced that Medicare drug plans (Part D or Medicare Advantage) could now cover Zepbound (tirzepatide) when doctors prescribe it to patients for obesity and sleep apnea. This is not the opening of floodgates. It is movement […]

Weight Loss Season: Faded, but Neither Gone nor Forgotten

January 7, 2025 — It used to be that this was the time of year when popular culture turned its attention to weight loss season. The release of U.S. News rankings of “Best Diets” commanded media attention. Weight loss tips were everywhere. But no more is this true. No, idle talk about weight loss has not disappeared. But it […]